<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837430</url>
  </required_header>
  <id_info>
    <org_study_id>2130-DHYD</org_study_id>
    <nct_id>NCT04837430</nct_id>
  </id_info>
  <brief_title>NT-proBNP and Troponin I in Dengue Children</brief_title>
  <official_title>NT-proBNP and Troponin I in Children With Dengue Hemorrhagic Shock: a Longitudinal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Le Phuoc Truyen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Medicine and Pharmacy at Ho Chi Minh City</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To discribe concentration of NT-proBNP and Troponin I in Dengue hemorrhagic shock children,&#xD;
      in correlation between concentration of NT-proBNP and troponin I with total fluid admission,&#xD;
      respiratory support, using inotrope and vasopressor using.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment of children with Dengue hemorrhagic shock syndrome (DSS) is challenge, especially&#xD;
      in cases with hypotensive shock, profound shock or whom do not have a response to initial&#xD;
      crystalloid therapy. Currently, treatment of DSS remains almost supportive, with particular&#xD;
      emphasis on careful fluid management. However, fluid overload is a common complication of&#xD;
      this treatment, lead to many difficulties in management of severe Dengue children, accompany&#xD;
      with morbidity and mortality. Diagnosis of fluid overload mostly based on clinical features&#xD;
      and chest X-ray or ultrasound. Until now, no biomarker are widely using for diagnosis of&#xD;
      fluid overload in clinical. NT-proBNP is secreted when stretching the wall of the cardiac&#xD;
      muscle. This may a suitable biomarker to discover the fluid overload state in children with&#xD;
      DSS. Troponin I is a biomarker of cardiac muscle damage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Days</target_duration>
  <primary_outcome>
    <measure>Concentration of NT-proBNP</measure>
    <time_frame>10 days</time_frame>
    <description>Concentration of NT-proBNP in Children with Dengue hemorrhagic shock and severe shock</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of Troponin I</measure>
    <time_frame>10 days</time_frame>
    <description>Concentration of Troponin I in Children with Dengue hemorrhagic shock and severe shock</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cut-off value of NT-proBNP for fluid overload</measure>
    <time_frame>14 days</time_frame>
    <description>Cut-off value of NT-proBNP for pulmonary edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between concentration of NT-proBNP</measure>
    <time_frame>14 days</time_frame>
    <description>Correlation between concentration of NT-proBNP with total fluid admission, respiratory support, using inotrope and vasopressor using</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between concentration of Troponin I</measure>
    <time_frame>14 days</time_frame>
    <description>Correlation between concentration of Troponin I total fluid admission, respiratory support, using inotrope and vasopressor using</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical manifestations</measure>
    <time_frame>14 days</time_frame>
    <description>Rate of clinical manifestations: fever, abdominal pain, petechia, hematomegaly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of abnormal laboratory exam</measure>
    <time_frame>14 days</time_frame>
    <description>electrolyte, arterial blood gas, lactate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of abnormal liver, kidney, hematology laboratory exam</measure>
    <time_frame>14 days</time_frame>
    <description>AST, ALT, ure, creatinin, PLT, PT, aPTT, Fibrinogen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of NS1 Dengue</measure>
    <time_frame>10 days</time_frame>
    <description>Positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MAC ELISA IgM Dengue</measure>
    <time_frame>14 days</time_frame>
    <description>Positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications</measure>
    <time_frame>14 days</time_frame>
    <description>Pulmonary edema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of respiratory support</measure>
    <time_frame>14 days</time_frame>
    <description>Cannula, NCPAP, Intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intubation</measure>
    <time_frame>14 days</time_frame>
    <description>Positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of mode of ventilation</measure>
    <time_frame>14 days</time_frame>
    <description>PC, IP, PEEP, FiO2, VT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total fluid administration</measure>
    <time_frame>14 days</time_frame>
    <description>ml/kg/d</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for IV fluid administration</measure>
    <time_frame>14 days</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and kind of cephalosporin using</measure>
    <time_frame>14 days</time_frame>
    <description>3rd generation cephalosporin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and kind of Carbapenem using</measure>
    <time_frame>14 days</time_frame>
    <description>Carbapenem</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate and kind of Vancomycin using</measure>
    <time_frame>14 days</time_frame>
    <description>Vancomycin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of intraperitoneal fluid drainage</measure>
    <time_frame>14 days</time_frame>
    <description>Positive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CRRT</measure>
    <time_frame>14 days</time_frame>
    <description>Positive</description>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Dengue Shock Syndrome</condition>
  <condition>Children, Only</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Children from 1 month to 15 years old are diagnosed with Dengue shock syndrome according to&#xD;
        guidelines of WHO with NS1 (+) or ELISA IgM Dengue (+)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Dengue shock children who admitted to ICU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Excluding the cases of children with cardiovascular disease, hyperthyroidism, taking&#xD;
             drugs such as insulin, steroid, estrogen, growth hormone, thyroid hormone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Truyen P. Le, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine and Pharmacy at Ho Chi Minh City</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Le P. Truyen, MD</last_name>
    <phone>+84 903640025</phone>
    <email>dr.letruyen@ump.edu.vn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Phung Nguyen, MD</last_name>
    <phone>84 989043858</phone>
    <email>nguyenphung@ump.edu.vn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of medicine and pharmacy at Ho Chi Minh city</name>
      <address>
        <city>Ho Chi Minh City</city>
        <zip>700000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Truyen P. Le</last_name>
      <phone>+84 903640025</phone>
      <email>dr.letruyen@ump.edu.vn</email>
    </contact>
    <investigator>
      <last_name>Truyen P. Le, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 3, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Medicine and Pharmacy at Ho Chi Minh City</investigator_affiliation>
    <investigator_full_name>Le Phuoc Truyen</investigator_full_name>
    <investigator_title>Clinical Physician</investigator_title>
  </responsible_party>
  <keyword>NT-proBNP</keyword>
  <keyword>Troponin I</keyword>
  <keyword>Dengue children</keyword>
  <keyword>Cardiac enzyme</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Severe Dengue</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

